Related links

External links

Share this page:
Other services (opens in new window)
Sets a cookie

Procarta secures major new investment to continue development of novel antibiotics

11 November 2010

Procarta, a spin-out company previously supported by BBSRC and emerging from John Innes Centre science, has secured up to £1.25M funding to continue the development of its novel DNA-based antibiotic technology to help combat drug-resistant infections.

Procarta Biosystems Ltd, which is developing a novel class of DNA-based antibiotics capable of tackling drug-resistant infections, announced today a round of equity investment totalling £730,000 with the potential to rise to £1.25M. The round was led by Morningside Venture Investments Limited and included Procarta's current investors, Rainbow Seed Fund and Iceni Seedcorn Fund.

Procarta's discovery initiatives target next generation of antibiotics to tackle the rising threat of superbugs. Procarta's flexible approach allows rapid development of drug candidates against challenging infections for which there are few therapeutic options. This raise will be applied to progress Procarta's anti-MRSA lead compound and deepen the company's already extensive pipeline, with particular emphasis on new therapeutics active against Gram-negative strains, such as Pseudomonas aeruginosa - a common complication associated with people with Cystic Fibrosis.

Dr Michael McArthur, Procarta's scientific co-founder and CSO, commented: "Coming on the back of positive scientific results, this raise validates the Procarta's platform's promise to cope with the emerging threat of antibiotic resistance. We are thrilled to see this capital infusion which will allow us to drive all of our programmes forward and build on the early-stage interest expressed by major pharmaceutical companies."

"Morningside is pleased to support the development of Procarta's innovative platform to help combat bacterial infections such as MRSA and Gram-negative infections," commented Dr. Isaac Cheng of Morningside. "The company has the potential to significantly beneficially impact one of the most serious public health challenges facing the world today- the rise of antibiotic resistance."

In conjunction with this investment, the company is strengthening its Board by appointing two investor Directors designated by Morningside and Rainbow alongside Dr David Knowles as the Chairman. David is internationally renowned as a pioneer of antibacterial research and a successful developer of therapeutics. David comes to Procarta with twenty years' experience in senior positions in major international pharmaceutical companies, including SmithKline Beecham, where he was Director of Molecular Biology. For the past ten years he has acted as CSO/R&D Director for several companies in the biotech sector in the UK (RiboTargets plc., British Biotech plc., Piramed Ltd, CellCentric) as well as advising other biotechs and Private Equity Funds in the UK, US, Europe and Asia.

"I am delighted that Procarta has secured this funding. The company's elegant therapeutic platform is potentially applicable to a wide range of bacterial diseases and Procarta can now advance its portfolio of much-needed anti-bacterials," said Dr Knowles.

Mark White of Rainbow commented "the fund-raising environment for early stage biotech is extremely difficult and we are delighted to have secured funding from a supportive investor such as Morningside. We have been highly impressed with the progress made so far by Michael McArthur and his team and we are delighted at his recent recognition as the Most Promising Innovator of the Year at the National BBSRC Innovator of the Year awards."

ENDS

External contact

Dr Michael McArthur, Procarta Biosystems Ltd

tel: 01603 450728

Contact

BBSRC Media Office

tel: 01793 414694